Divis Laboratories Ltd (DIVISLAB) Q1 FY27 Results Analysis: PAT Surges 66%, Revenue Jumps 28%

Divis Laboratories Ltd reported Q1 FY27 numbers with revenue of Rs. 3,080.00 Cr (+27.80% YoY) and PAT growth of +65.50% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Divis Laboratories delivered a record Q1 with revenue up 27.8% YoY and PAT up 65.5%, beating its own annual guidance on both revenue and margin. The Biosecure Act provides a structural tailwind, and operating leverage is evident. However, the large inventory drawdown and forex headwind warrant monitoring, as margin expansion may partly reverse.

Key Investment Insights

Key Positives

• Consolidated revenue grew 27.8% YoY to Rs.3,080 Cr, a record for any Q1.
• PAT grew 65.5% YoY to Rs.902 Cr, also a Q1 record.
• EBITDA margin (P&L-derived) expanded 10.5 pp YoY to 40.75%.
• EBIT margin of 38.51% exceeded management's guided range of 32-32.5%.
• Custom synthesis momentum and the Biosecure Act provide structural growth tailwinds.
• Operating leverage visible as employee cost and other expenses declined as a % of revenue.

Risk Factors

• Forex swung from a gain of Rs.39 Cr to a loss of Rs.7 Cr YoY, a headwind of ~Rs.46 Cr.
• Gross material cost as % of revenue rose sharply from 41.91% to 48.80% YoY, indicating input cost pressure.
• The large inventory drawdown of Rs.517 Cr (vs Rs.54 Cr) is a non-cash benefit that may normalize, pressuring future margins.
• Cost of materials consumed increased 48.81% YoY, outpacing revenue growth of 27.8%.